Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1/2 6Phase NA 4Phase 3 3Phase 1 3Phase 2/3 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Multiple Myeloma 3Burkitt Lymphoma 3Neuroblastoma 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Biphenotypic, Acute 2Leukemia 2Ganglioneuroblastoma 2Smoldering Multiple Myeloma 1Rhabdoid Tumor 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Medulloblastoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Leukemia, Myelomonocytic, Juvenile 1Immunoglobulin Light-chain Amyloidosis 1Hemoglobinuria, Paroxysmal 1Hemoglobinuria 1Breast Neoplasms 1

Interventions

Dexamethasone 169Bortezomib 92Lenalidomide 85daratumumab 44Thalidomide 44pomalidomide 43Melphalan 40Cyclophosphamide 33carfilzomib 29Calcium Dobesilate 27Prednisone 19Doxorubicin 16elotuzumab 14isatuximab 12Filgrastim 12ixazomib 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10belantamab mafodotin 9Granulocyte Colony-Stimulating Factor 9Zoledronic Acid 8selinexor 7dexamethasone acetate 7Epoetin Alfa 7Etoposide 6fludarabine 5Cisplatin 5Carmustine 5iberdomide 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Multiple Myeloma × Stem Cell Transplantation × Clear all
NCT00114101 2026-05-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

NCT03595800 2024-10-04

HaploMUD-RIC

Institut Paoli-Calmettes

Phase 3 Completed
9 enrolled
LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT01413178 2020-04-21

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

M.D. Anderson Cancer Center

Phase 3 Completed
205 enrolled 11 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡